Compare Pfizer Inc (PFE) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Global X Uranium ETF — how do they compare? Pfizer Inc trades at $28.28 (market cap $158.56B), while Global X Uranium ETF trades at $38.9 (market cap $5.48B). The key difference: Pfizer Inc is far larger — about 28.9× Global X Uranium ETF's market cap, and Pfizer Inc pays a 6.18% dividend while Global X Uranium ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Global X Uranium ETF for 62 Days on average.
| PFE | URA | |
|---|---|---|
Market Cap | $158.56B | $5.48B |
Volume | 44,138,282 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $29.02 | $61.81 |
52-Week Low | $23.67 | $37.52 |
Typical Hold Time | 158 Days | 62 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
URA (Global X Uranium ETF) is trading at $38.56, down 3.43% amid bearish technical signals with 19 sell indicators versus 3 buy signals. The ETF faces pressure despite positive nuclear energy sector news, including government funding commitments and growing AI power demand. Current price sits near key support at $38 with resistance at $39.
The uranium sector shows long-term potential with nuclear energy expansion and AI power needs, but URA faces near-term volatility from commodity price sensitivity and concentrated holdings. Investors should weigh structural supply deficits against technical weakness and sector-specific risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
